Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intrathecal Administration of MELPIDA (AAV9/AP4M1) for Hereditary Spastic Paraplegia Type 50 (SPG50): a Phase 3, Open-Label Trial with Matched Prospective Concurrent Control Arm

Next Previous
Trial Profile

Intrathecal Administration of MELPIDA (AAV9/AP4M1) for Hereditary Spastic Paraplegia Type 50 (SPG50): a Phase 3, Open-Label Trial with Matched Prospective Concurrent Control Arm

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Melpida-Elpida Therapeutics (Primary)
  • Indications Hereditary-spastic paraplegia
  • Focus Registrational; Therapeutic Use
  • Acronyms SPG50
  • Sponsors Elpida Therapeutics

Most Recent Events

  • 21 Jan 2026 Planned initiation date changed from 1 Mar 2025 to 1 Feb 2025.
  • 21 Jan 2026 Status changed from not yet recruiting to recruiting.
  • 26 Nov 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top